Tango's Vopimetostat Combos Show 92% Response Rate in Pancreatic Cancer

What happened

Tango Therapeutics reported initial Phase 1/2 data for vopimetostat plus Revolution Medicines' daraxonrasib in MTAP-deleted, RAS-mutant metastatic pancreatic cancer, demonstrating a 92% objective response rate and a 90% 6-month progression-free survival rate with median PFS not yet reached. The combination was generally well-tolerated, supporting rapid advancement into Phase 3 development in first-line pancreatic cancer. While the data are early and from a small cohort, they validate the preclinical synergy between PRMT5 and RAS inhibition and could meaningfully expand the addressable market. However, the stock has already rallied 350% over the past year, and the company remains pre-revenue with no randomized data yet. The master report maintains a Potential Sell rating, noting that the valuation already discounts substantial success, leaving limited margin of safety.

Implication

The 92% response rate is a strong validation of the combination strategy and could accelerate Phase 3 initiation, potentially leading to first-in-class approval. However, the data are from a small early-stage cohort and need to be confirmed in larger randomized trials. Tango's cash runway into 2028 provides some buffer, but the company still requires substantial additional funding. With the stock up 350% over the past year, much of the potential success is already priced in, leaving limited upside unless data continue to outperform. Given the high execution risk and competitive threats, investors should wait for a pullback to de-risk entry points.

Thesis delta

The new data significantly de-risks the combination approach and increases the probability of a successful pivotal trial, shifting our base case probability upward. However, the stock's current valuation already incorporates a high likelihood of success, so we maintain our Potential Sell rating with a higher conviction in the bull case scenario. We would consider upgrading if the stock pulls back to attractive entry levels.